Siemens Healthineers has agreed a €200 million ($224 million) deal to buy the diagnostic arm of Novartis' Advanced Accelerator Applications (AAA) radiopharma unit, boosting its medical imag
The life sciences industry is currently undergoing a significant transformation, driven by the rapid development of new modalities such as cell and gene therapies (CAGT), and substantial ne
Eli Lilly has lined up another deal in the radiopharmaceutical sector, paying $140 million to partner drugs developed by Radionetics Oncology and taking an option on buying the company outr
Just days after Telix priced a $200 million initial public offering (IPO) in the US, the Australian radiopharmaceutical specialist has abandoned the plan.